Today, Friday, April 27, 2018 is the last day of trading in Kancera's share, including the right to participate in the rights issue.

Otherwise, the following time plan applies (dates refer to 2018): 

Friday April 27thLast day for trading of shares including the right to participate in New Issue with preferential rights

Monday April 27th: First day for trading of shares excluding the right to participate in New Issue with preferential rights

Wednesday May 2nd; Reconciliation day for the acquisition of unit rights and rights to participate in the New Issue with preferential rights

Friday May 4th: Subscription period begins, trading of unit rights starts

Friday May 18th: Trade in unit rights is concluded

Tuesday May 22nd:The subscription period ends

Friday May 25th: Publication of results of the New Issue

About Kancera
Kancera AB is engaged in the development of pharmaceuticals that begin with new treatment concepts and end with the sale of a drug candidate to international pharmaceutical companies. Currently, Kancera AB is developing cancer drugs by controlling the immune system, arresting survival signals in the cancer cell and preventing the cancer cell's ability to repair. Kancera AB operates in Karolinska Institutet Science Park in Stockholm and employs approximately 18 people. The share is traded on NASDAQ First North. The number of shareholders was approximately 7,300 on March 29, 2018. FNCA Sweden AB is Kancera AB's Certified Adviser. Professor Carl-Henrik Heldin, Professor Håkan Mellstedt and MD PhD Charlotte Edenius are scientific advisors and board members in Kancera AB.

For further information, contact:

Erik Nerpin, Chairman of the Board, 070-620 73 59

Thomas Olin, CEO: 0735-20 40 01

Kancera AB (publ)
Karolinska Science Park,
Banvaktsvägen 22
171 48 Solna

Visit our web site at: http://www.kancera.se